Skip to main content
Caplight Logo









Imel Biotherapeutics

Imel Biotherapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://imelbiotx.com/

Last Round

Series A

Nov 15, 2021

Total Funding Raised

$15M

Company Overview

Imel Biotherapeutics is a biotechnology company that develops cell-based therapies designed to treat patients with mitochondrial disorders and age-related indications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapymitochondrial replacement therapyMirCimmunotherapyoncologyinflammatory diseasepreclinical developmentbiotech startupdrug discoveryT cell therapynext-gen biotechtherapeutic pipelinecell engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Imel Biotherapeutics Comparables

Compare Imel Biotherapeutics with similar companies based on industry and business-model similarity.

Imel Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MitoRx Therapeutics
57%
PAEAN Biotechnology
57%
Altos Labs
56%

Imel Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 15, 2021

Imel Biotherapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 15, 2021

    $15M round led by Remiges Ventures

Imel Biotherapeutics Filings

Explore SEC and related filing metadata, where available.

Imel Biotherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Imel Biotherapeutics's valuation, stock price, and market status.

Is Imel Biotherapeutics a public or private company?

Imel Biotherapeutics is a private company.

What is the current stock price of Imel Biotherapeutics?

Imel Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Imel Biotherapeutics worth (valuation)?

Valuation information for Imel Biotherapeutics is not publicly available.

Can I buy Imel Biotherapeutics stock?

Imel Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Imel Biotherapeutics's last funding round?

Imel Biotherapeutics's most recent funding round was Series A on November 15, 2021.

Who are the main investors in Imel Biotherapeutics?

Key investors in Imel Biotherapeutics include Remiges Ventures.

Will Imel Biotherapeutics IPO soon?

No public IPO plans have been announced for Imel Biotherapeutics.

How can I track Imel Biotherapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Imel Biotherapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range1
Year Founded2019
Last FundingNov 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?